Posted by Michael Wonder on 17 Mar 2021
AbbVie announces extension of review for supplemental new drug application of upadacitinib for the treatment of adults with active psoriatic arthritis
17 March 2021 - AbbVie announced that the U.S. FDA has extended the review period for the supplemental new drug application for upadacitinib in the treatment of adult patients with active psoriatic arthritis.
The updated Prescription Drug User Fee Act action date has been extended three months to late Q2 2021.
